Gene therapy utilizing adeno-associated viruses (AAV) has emerged as a pivotal advancement in the treatment of autosomal recessive hereditary deafness, offering a beacon of hope for hearing restoration to millions of patients globally. This innovative approach involves delivering functional genes to the inner ear, thereby repairing damaged auditory structures and enhancing hearing capabilities.